Fulvic acid and antibiotic combination for the inhibition or treatment of multi-drug resistant bacteria
AssigneeNatracine UK Limited
InventorsStephen William Leivers, Peter Warn
Life of this patent
Estimating the term…
Abstract
Fulvic acid as the active ingredient is used in the treatment or inhibition of multi-drug resistant bacteria, in particular NDM-1 bacteria producing carbapenemase or extended-spectrum lactamase (ESBL) resistant bacteria. The multi-drug resistant bacteria may be gram negative bacteria including, but not limited to, Klebsiella pneumoniae or Escherichia coli. The fulvic acid can be provided in combination with one or more antibiotics from the class of carbapenems or polymyxin antibiotics.
Claims21
A method of treating, killing, or inhibiting growth of, multi-drug resistant bacteria in a subject wherein the multi-drug resistant bacteria are NDM-1 positive bacteria producing carbapenemase, or extended-spectrum β-lactamase (ESBL) resistant bacteria, comprising administering to the subject an amount of a composition comprising fulvic acid, or a salt thereof, or a combination of fulvic acid and a salt thereof as the active ingredient effective to treat, kill or inhibit growth of, such bacteria in the subject.
(canceled)
A method of treating, killing, or inhibiting growth of, multi-drug resistant bacteria in a subject comprising administering to the subject an amount of a composition comprising fulvic acid, or a salt thereof, as an active ingredient together with one or more antibiotics selected from the group of carbapenems or polymyxin antibiotics so as to treat, kill, or inhibit growth of, such bacteria in the subject.
12-14. (canceled)
16-18. (canceled)
Dependencies are inferred from the claim text.